#USA #healthcare #Jefferies Conference #Castle Biosciences #Friendwood

Castle Biosciences at the 2026 Jefferies Global Healthcare Conference

Castle Biosciences, Inc. (Nasdaq: CSTL), a leading innovator in health diagnostics, has announced its participation in the upcoming 2026 Jefferies Global Healthcare Conference. This notable event is scheduled for June 3, 2026, at 12:00 PM Eastern Time. As an influential company committed to advancing patient care, Castle Biosciences plans to offer an in-depth overview during this key presentation.

The medical community increasingly relies on Castle Biosciences for its groundbreaking tests designed to guide patient treatment. The firm specializes in developing personalized, clinically actionable solutions that empower healthcare professionals and patients alike. With specific focus areas in dermatologic and gastroenterological diseases, Castle Biosciences aims to enhance disease management and patient outcomes through innovative testing methodologies.

A live audio webcast of the presentation will be accessible through the company’s official website, allowing interested stakeholders to engage with the content in real-time. Additionally, a recording of the broadcast will be available for review after the event concludes, ensuring that those who cannot attend live can still benefit from the shared insights.

About Castle Biosciences

Castle Biosciences is at the forefront of developing diagnostic solutions that not only inform care decisions but also help improve health outcomes. Their commitment to science and technology is reflected in their array of cutting-edge tests, including DecisionDx-Melanoma, i31-SLNB, and TissueCypher among others. These tests exemplify the company’s goal to empower both clinicians and patients through meaningful and actionable health data.

The company's ethos centers around putting people first, ensuring that enhanced patient care remains the priority. Castle Biosciences has pioneered methods that combine rigorous scientific research with advanced molecular testing to support confident treatment planning for practitioners and patients.

To learn more about the innovative products and solutions Castle Biosciences offers, visit Castle Biosciences’ website and connect with them on social media platforms including LinkedIn, Facebook, X, and Instagram.

In light of their upcoming presentation at the Jefferies Conference, interest is likely to rise around Castle Biosciences' capabilities in the medical diagnostics field. Stakeholders and investors will be keen to see the impact of the company's innovative solutions on enhancing patient care and overall health prognosis. With a strong focus on science and technology, Castle Biosciences is poised to contribute significantly to the healthcare landscape in the near future.

For any press-related inquiries, Camilla Zuckero serves as the Investor Contact, while Allison Marshall is available for media queries as indicated in the company's communications.

This conference will indeed serve as a platform for Castle Biosciences to highlight their achievements and future directives, marking a pivotal moment in their growth trajectory within the health sector.